XEED
Live / Allowed — Notice of allowance issued (as of 11 Aug 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 09 Jun 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99225625
- Mark type
- Word mark
- Filed
- 09 Jun 2025
- Published for opposition
- 16 Jun 2026
- Attorney of record
- Gina L. Durham
Goods and services
- Class 005 — Pharmaceuticals: Diagnostic kits comprised of medical diagnostic reagents and assays for testing of exosomes and other extra-cellular vesicles for use in disease detection, namely, autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, reproductive, and viral diseases and disorders; medical diagnostic reagents and assays for testing of exosomes and other extra-cellular vesicles in the fields of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, reproductive, and viral diseases and disorders
- Class 010 — Medical apparatus: Medical apparatus and instrument for diagnostic use, namely, apparatus for medical diagnostic testing in the fields of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, reproductive, and viral diseases and disorders; medical diagnostic apparatus for detecting autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, reproductive, and viral diseases and disorders; medical diagnostic apparatus, namely, lab-on-a-chip systems comprised of microelectrode arrays and microfluidic controllers, pumps, and valves for use in biological analysis; apparatus for carrying out diagnostic cell-based testing for medical purposes; diagnostic apparatus for autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, reproductive, and viral diseases and disorders, namely, medical diagnostic apparatus for testing cell-derived vesicles or extra-cellular vesicles and detecting autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, infectious, inflammatory, kidney, liver, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, respiratory, reproductive, and viral diseases and disorders; Medical apparatus and instrument for diagnostic use, namely, apparatus for medical diagnostic testing in the field of oncology; medical diagnostic apparatus for detecting cancer; diagnostic apparatus for cancer diseases, namely, medical diagnostic apparatus for testing cell-derived vesicles or extra-cellular vesicles and detecting cancer; none of the foregoing comprising wearable movement tracking devices.
- Class 044 — Medical, beauty and agricultural services: Medical testing for diagnostic and treatment purposes
Owner
- Xzom, Inc., San Diego, CA, US
- Xzom, Inc., San Diego, CA, US
Prosecution history
- 11 Aug 2026 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 16 Jun 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 16 Jun 2026 — PUBLISHED FOR OPPOSITION
- 10 Jun 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 20 May 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 20 Apr 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 20 Apr 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 20 Apr 2026 — TEAS REQUEST FOR RECONSIDERATION RECEIVED
- 27 Feb 2026 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 27 Feb 2026 — FINAL REFUSAL E-MAILED
- 27 Feb 2026 — FINAL REFUSAL WRITTEN
- 30 Jan 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 30 Jan 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 30 Jan 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 29 Jan 2026 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED